

**Regd. Office :**  
'Zydus Tower',  
Satellite Cross Roads,  
Ahmedabad 380 015. India.  
Phone : +91-79-2686 8100 (20 Lines)  
Fax : +91-79-2686 2368  
www.zyduscadila.com  
CIN:L24230GJ1995PLC025878

August 30, 2017

**BSE Limited**  
1<sup>st</sup> Floor, P J Towers,  
Dalal Street,  
Mumbai – 400 001

**National Stock Exchange of India Limited**  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (East),  
Mumbai – 400 051

Re.: **Press Release**

Dear Sir / Madam,

We enclose herewith a copy of press release dated August 30, 2017 titled "Zydus receives final approval from the USFDA for Aspirin and Extended-Release Dipyridamole Capsules".


The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking You,

Yours faithfully,  
For, **CADILA HEALTHCARE LIMITED**

  
**UPEN H. SHAH**  
**COMPANY SECRETARY**



Encl.: As above

## **Zydus receives final approval from the USFDA for Aspirin and Extended-Release Dipyridamole Capsules**

*Ahmedabad, 30 August 2017*

Zydus Cadila has received the final approval from the USFDA to market Aspirin and Extended-Release Dipyridamole Capsules in the strength of 25 mg/200 mg. The drug is an antiplatelet agent which works in the prevention of excessive blood clotting and is used to reduce the risk of stroke in patients who have had or are at risk of stroke.

The drug will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad. The sales of Aspirin and Extended-Release Dipyridamole Capsules are estimated at \$198.7 million. *Source: IMS Health, IMS National Sales Perspective Audit, MAT July 2017, extracted August 2017.*

The group now has more than 140 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

\*\*\*